SRTA

#2912
Strata Critical Medical, Inc. - Class A Common Stock
5.6 6 USD
-0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
5.66
5.66
Intervallo Annuale
3.85
6.50
Variazione giornaliera
-5.19%
Variazione Mensile
+12.08%
Variazione di 6 mesi
+34.76%
Variazione Annuale
+31.02%
Chiusura Precedente
5.9 7
Open
5.6 6
Minimo
5.6 6
Massimo
5.6 6
Volume
102
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Strata Critical Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Strata Critical Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Strata Critical Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Strata Critical Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K

Strata Critical Medical, Inc. current report, Q1 FY2023

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Blade Air Mobility, Inc. (not Strata Critical Medical, Inc.) on March 30, 2023. The filing discloses corporate governance changes, specifically the entry into a material definitive agreement with RB Lift, LLC, and the appointment of two new independent directors to the Board of Directors.

Key Financial Metrics

This filing is a current report regarding corporate events and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.

Material Changes and Corporate Actions

  • Nomination Rights Agreement: On March 27, 2023, the Company entered into an agreement with RB Lift, LLC. As long as RB Lift beneficially owns at least 5% of the Company's common stock, it has the right to nominate one director (the "RedBird Nominee") to the Board as a Class II director.
  • Director Appointments: The Board appointed John Borthwick (Class I director, term expires 2025) and Andrew Lauck (Class II director, term expires 2023) as independent directors effective March 27, 2023.
  • Committee Assignments: Mr. Borthwick was appointed to the Nominating and Corporate Governance Committee. Mr. Lauck was appointed to the Audit Committee.
  • Termination of Observer Rights: The previous Observation Rights Agreement with RB Lift terminated upon Mr. Lauck's appointment as a voting director.

Guidance, Outlook, and Compensation

  • Compensation: Mr. Borthwick will be compensated per the Company's standard policies for non-employee directors. Mr. Lauck will not receive cash compensation other than expense reimbursement and participation in the flight benefit policy.
  • Agreement Duration: The Nomination Rights Agreement remains in effect until the earlier of the 2026 annual meeting, RB Lift's ownership dropping below 5%, or mutual written consent to terminate.
  • Outlook: The filing contains no financial guidance or operational outlook.

Investor Verification Checklist

  • Verify the current beneficial ownership percentage of RB Lift, LLC to confirm the active status of the Nomination Rights Agreement.
  • Review the full text of the Nomination Rights Agreement (Exhibit 10.1) for specific conditions regarding the Audit Committee appointment.
  • Confirm the independence status of the new directors, particularly Mr. Lauck, given his role as President of RB Lift.
  • Check subsequent filings for the outcome of the 2023 annual meeting regarding Mr. Lauck's Class II director term.